Sage Therapeutics, Inc. (SAGE) reported a loss of $1.70 per share for the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of$1.68. The company had reported a loss of $2.68 per share in the year-ago quarter.Revenues in the second quarter totaled$8.6 million, significantly up from $2.5 million reported in the year-ago period. The upside can be attributed to strong uptake for the recently launched depression drug Zurzuvae (zuranolone), which is marketed in partnership with drug gian ...